Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...

Gilead’s efforts to innovate its HIV portfolio are impressive. The company’s pipeline candidate, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in ...

If all of its National Institutes of Health funding falls away, the country could lose 70% of its medical research capacity ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.